When:
October 6, 2021 1:00 pm – October 6, 2021 2:30 pm PDT
Where:
Virtual
Biocom California, Online Event, Register: https://www.biocom.org/EventDetail/?event=Venture-Day-Viva-BioInnovator
October 6th, Viva BioInnovator will be hosting a plenary session where they will discuss their Corporate Venture Arm, areas of interest, investment thesis and host a Q&A panel to NewYorkBio and Biocom California members. There will also be one-on-one meeting opportunities with California and New York-based entrepreneurs, biotech companies, institutions, and entrepreneurs looking to raise capital on October 7th. Information on how to sign up for the plenary session and apply for a one-on-one meeting can be found below.
Agenda:
- 1:00pm PT/4:00pm ET – Introductions from NewYorkBio & Biocom California
- 1:15pm PT/4:15pm ET – Overview of fund, investment strategy, areas of focus by Viva BioInnovator
- 2:00pm PT/5:00pm ET – Q&A
Viva BioInnovator is the specialized investment and incubation arm of Viva Biotech Holdings. They focus on the identification and success of early stage of biotech startups across all indications and drug types. It’s during these early stages, they can nurture and accelerate a startup’s seeding and growth from an idea into clinical programs.
Since their inception in 2017, they have continued to evolve and optimize their investment model as they try to ensure the success of their portfolio companies. In addition to their cash and in-kind investments through Viva’s drug R&D service division, introduction to industry networks, and operational assistance, etc., they established a dual track in-person support team through their “Venture Partners” and “Business Partners.” This support team gives their founders crucial access to advice and resources from both a scientific perspective as well as a business and compliance perspective. Additionally, VBI can provide solid support in BD, financial advising, and more for their founders as part of their baseline services. Beyond Viva’s in-house capabilities, they are building a drug development supplier network including organizations such as CMCs, CMOs, or clinical CROs.
As of early 2021, VBI has invested in over 60 companies out of the thousands of proposals submitted for review and they plan to invest at a rapid pace in the years to come. Their seed or A-round funding is typically in the range of $500K – $5 Million.
VBI investment focuses primarily on innovative therapeutics. They assess investment opportunities based on four dimensions:
- Insisting the founders have high integrity with a successful track record of building a company and/or developing a drug.
- The “idea” needs to be innovative
- There must be a true unmet medical need.
- They invest in opportunities with significant market potential 5-10 years in the future.
How to Apply:
If you are working on innovative therapeutics in the areas listed above and interested in meeting with the VBI Investment Team, please apply on the link below by Friday, September 17th for consideration.
*Please note that this is an opportunity to apply to meet one-on-one with the VBI team to discuss your company, pipeline and technologies. The one-on-one meeting is not open to public; meetings are by invitation only
